{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:24:38Z","timestamp":1788801878136,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s11934-014-0463-9","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T08:26:41Z","timestamp":1413188801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["The Role of Inflammation in Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) and Its Potential Impact on Medical Therapy"],"prefix":"10.1007","volume":"15","author":[{"given":"Vincenzo","family":"Ficarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rossanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Zazzara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Giannarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Abbinante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"463_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eursup.2013.08.001","volume":"12","author":"MJ Ribal","year":"2013","unstructured":"Ribal MJ. The link between benign prostatic hyperplasia and inflammation. Eur Urol Suppl. 2013;12:103\u20139.","journal-title":"Eur Urol Suppl"},{"key":"463_CR2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/path.2077","volume":"211","author":"N Sampson","year":"2007","unstructured":"Sampson N, Untergasser G, Plas E, Berger P. The ageing male reproductive tract. J Pathol. 2007;211:206\u201318.","journal-title":"J Pathol"},{"key":"463_CR3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","volume":"54","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Roehrborn CG, O\u2019Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379\u201384.","journal-title":"Eur Urol"},{"key":"463_CR4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","volume":"60","author":"C Nunzio De","year":"2011","unstructured":"De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106\u201317. This is a very comprehensive review article investigating the relationship between inflammation and benign prostatic hyperplasia. The article suggested that chronic prostatic inflammation may be involved in the development and progression of chronic prostatic disease, although there is still no evidence of a causal relation. Inflammation should be considered a new domain in basic and clinical research in patients with BPH.","journal-title":"Eur Urol"},{"key":"463_CR5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pros.10238","volume":"56","author":"GE Steiner","year":"2003","unstructured":"Steiner GE, Newman ME, Paikl D, et al. Expression and function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56:171\u201382.","journal-title":"Prostate"},{"key":"463_CR6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.LAB.0000081388.40145.65","volume":"83","author":"GE Steiner","year":"2003","unstructured":"Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83:1131\u201346.","journal-title":"Lab Invest"},{"key":"463_CR7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eursup.2013.08.002","volume":"12","author":"V Ficarra","year":"2013","unstructured":"Ficarra V, Sekulovic S, Zattoni F, Zazzara M, Novara G. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110\u20135. This review describes the recent literature regarding the relationship between prostatic inflammation and BPH and focuses on the clinical perspective of why and how to evaluate prostatic inflammation. The article highlighted the potential role of biomarkers, prostatic calcifications, symptoms severity, and metabolic syndrome to identify clinically patients with suspicious prostatic inflammation.","journal-title":"Eur Urol Suppl"},{"key":"463_CR8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bju.12177","volume":"112","author":"V Ficarra","year":"2013","unstructured":"Ficarra V. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)? BJU Int. 2013;112:421\u20132.","journal-title":"BJU Int"},{"key":"463_CR9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bju.12118","volume":"112","author":"G Gandaglia","year":"2013","unstructured":"Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432\u201341. In this review article, the authors highlighted that although the histological examination of prostatic tissue remains the only available method to diagnose chronic inflammation, different parameters, such as prostatic calcifications, prostate volume, LUTS severity, storage and prostatitis-like symptoms, poor response to medical therapies, and urinary biomarkers, have been shown to be correlated with chronic inflammation.","journal-title":"BJU Int"},{"key":"463_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eursup.2009.11.004","volume":"8","author":"G Robert","year":"2009","unstructured":"Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl. 2009;8:879\u201386.","journal-title":"Eur Urol Suppl"},{"key":"463_CR11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2011.11.013","volume":"61","author":"C Nunzio De","year":"2012","unstructured":"De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560\u201370.","journal-title":"Eur Urol"},{"key":"463_CR12","unstructured":"Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Eur Assoc Urol. Web site http:\/\/www.uroweb.org ."},{"key":"463_CR13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2013.01.018","volume":"64","author":"C Fullhase","year":"2013","unstructured":"Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for nonneurogenic male lower urinary tract symptoms. Eur Urol. 2013;64:228\u201343.","journal-title":"Eur Urol"},{"key":"463_CR14","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.eururo.2007.03.034","volume":"51","author":"S Madersbacher","year":"2007","unstructured":"Madersbacher S, Marszalek M, Lackner J, et al. The long-term outcome of medical therapy for BPH. Eur Urol. 2007;51:1522\u201333.","journal-title":"Eur Urol"},{"key":"463_CR15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/nau.20475","volume":"26","author":"GJ Christ","year":"2007","unstructured":"Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007;26:948\u201354.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"463_CR16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/nau.22467","volume":"33","author":"M Hennenberg","year":"2014","unstructured":"Hennenberg M, Stief CG, Gratzke C. Prostatic \u03b11-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn. 2014;33(7):1074\u201385.","journal-title":"Neurourol Urodyn"},{"key":"463_CR17","doi-asserted-by":"crossref","unstructured":"Kwon YK, Choe MS, Seo KW, et al. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol. 2010;51:266\u201370. This prospective clinical study\u00a0showed\u00a0that in patients with high-grade prostatic inflammation the use of alpha-blockers combined with 5-alpha-reductase inhibitors\u00a0can be insufficient to reduce symptom severity, thus highlighting\u00a0the need for alternative drugs.\u00a0","DOI":"10.4111\/kju.2010.51.4.266"},{"key":"463_CR18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.eursup.2013.08.003","volume":"12","author":"A Taille de la","year":"2013","unstructured":"de la Taille A. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116\u201323. This review article examined the evidence for the role of inflammation in BPH and the use of various drug classes to reduce and prevent prostatic inflammation, with a particular focus on hexanic lipidosterolic extract of Serenoa repens (Permixon). Scientific evidence supports the conclusion that hexanic extract of Serenoa repens treats BPH through several mechanisms, one of which is reduction of inflammation.","journal-title":"Eur Urol Suppl"},{"issue":"2","key":"463_CR19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1464-410X.2012.11559.x","volume":"111","author":"A Kahokehr","year":"2013","unstructured":"Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111(2):304\u201311.","journal-title":"BJU Int"},{"key":"463_CR20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2005.08.014","volume":"49","author":"E Colli","year":"2006","unstructured":"Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006;49:82\u20136.","journal-title":"Eur Urol"},{"key":"463_CR21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2010.05.045","volume":"58","author":"JN Cornu","year":"2010","unstructured":"Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol. 2010;58:450\u20136.","journal-title":"Eur Urol"},{"key":"463_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1464-410X.2012.11144.x","volume":"110","author":"A Latil","year":"2012","unstructured":"Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1\/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:301\u20137.","journal-title":"BJU Int"},{"key":"463_CR23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0302-2838(03)00368-3","volume":"44","author":"R Vela Navarrete","year":"2003","unstructured":"Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, L\u00f3pez FA. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549\u201355.","journal-title":"Eur Urol"},{"key":"463_CR24","unstructured":"Exploratory study of L.S.E.S.r. (lipidosterolic extract of Serenoa repens) (PERMIXON1 160 mg hard capsule) versus tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH (benign prostatic hyperplasia) (PERMIN). NCT01604811. ClinicalTrials.gov Web site. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01604811?term=serenoa+repens&rank=4 ."}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-014-0463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-014-0463-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-014-0463-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T04:05:16Z","timestamp":1565928316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-014-0463-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1007\/s11934-014-0463-9","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]},"article-number":"463"}}